| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 07/31/2003 | US20030144270 Neurokinin receptor antagonists comprising heterocyclic amides used as antiemetics, antidepressants and/or antitussive agents |
| 07/31/2003 | US20030144267 Novel compounds |
| 07/31/2003 | US20030144266 Pyrazolo-triazolo- pyrimidine, triazolo-triazolo-pyrimidine and imidazolo-triazolo-pyrimidine derivatives useful for the treatment of hypertension, inflammation, mast cell degranulation, cardiac hypoxia, and ischemia |
| 07/31/2003 | US20030144253 Useful for treating or preventing neuronal damage associated with neurological diseases |
| 07/31/2003 | US20030144247 Obtained by reacting polyalkylene glycol or a reactive derivative, a phospholipid and a drug with each other to form covalent bonds to form a delivery substance |
| 07/31/2003 | US20030144239 Expression system |
| 07/31/2003 | US20030144234 Administering a cathepsin modulator or enzyme inhibitor, select from a mRNA or a protein; gene expression inhibition, analgesics |
| 07/31/2003 | US20030144233 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides |
| 07/31/2003 | US20030144232 Expression system |
| 07/31/2003 | US20030144211 Inhibit leukocyte adhesion to endothelium or to platelets |
| 07/31/2003 | US20030144203 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 07/31/2003 | US20030143690 Peptides and proteins that effect protein phosphorylation; genetic engineered DNA; useful for therapy and diagnosis |
| 07/31/2003 | US20030143684 Combining a compound to be tested, a host cell expressing a recombinant protein containing a mammalian C-C chemokine receptor 3 and a ligand for binding of ligand to such receptor, detecting the formation of a receptor-ligand complex |
| 07/31/2003 | US20030143676 Receptor polypeptides and polynucleotides encoding such polypeptides; for treating a disorder characterized by an elevated level of osteopontin |
| 07/31/2003 | US20030143620 Carbohydrate ligands specific for MHC molecules |
| 07/31/2003 | US20030143589 Drug metabolizing enzymes |
| 07/31/2003 | US20030143588 Phosphodiesterases |
| 07/31/2003 | US20030143290 As anti-inflammatory and anti-arthritic agents |
| 07/31/2003 | US20030143288 Topical anti-inflammatory compositions and methods of reducing inflammation |
| 07/31/2003 | US20030143271 For therapy and prophylaxis of cyclooxygenase-2 mediated disorder and for providing cardioprotection |
| 07/31/2003 | US20030143249 Method of treating pain |
| 07/31/2003 | US20030143246 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 07/31/2003 | US20030143230 Combination of an IL-1/18 inhibitor with a TNF inhibitor for the treatment of inflammation |
| 07/31/2003 | US20030143226 For therapy of arteriosclerosis, thrombocytopenia, kidneyd iseases, various types of inflammation such as myocardial ischemic reperfusion injury, inflammatory reactions after percutaneous transluminal coronary recanalization (PTCR)) |
| 07/31/2003 | US20030143223 Modulating the activity of one or more elements in the complement/lipid pathway |
| 07/31/2003 | US20030143192 Chemokine beta-7 |
| 07/31/2003 | US20030143185 Polymer conjugates of protein kinase C inhibitors |
| 07/31/2003 | CA2514088A1 Use of cholinesterase antagonists to treat insulin resistance |
| 07/31/2003 | CA2511238A1 Pteridine derivatives, method for the production thereof, and use thereof |
| 07/31/2003 | CA2510751A1 Multimers of receptor-binding ligands |
| 07/31/2003 | CA2476984A1 Lactoferrin as an agent for enhancing action of an opioid |
| 07/31/2003 | CA2476773A1 Monoclonal antibodies against extracellular loops of c5ar |
| 07/31/2003 | CA2474623A1 Peptides and nucleic acids of the cathelicidin family, derived from fish, and uses thereof |
| 07/31/2003 | CA2474269A1 Nutraceuticals for the treatment, protection and restoration of connective tissues |
| 07/31/2003 | CA2473796A1 Substituted quinazolin-4-ylamine analogues |
| 07/31/2003 | CA2473786A1 Method of prophylaxis against large myocardial infarctions |
| 07/31/2003 | CA2473781A1 Glycoisoforms of adiponectin and uses thereof |
| 07/31/2003 | CA2473740A1 Methods of treating conditions associated with an edg receptor |
| 07/31/2003 | CA2473707A1 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof |
| 07/31/2003 | CA2473545A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | CA2473490A1 Peptide-carrying bodies for immune response |
| 07/31/2003 | CA2473395A1 Phospholipid bodies and use thereof in medical treatment |
| 07/31/2003 | CA2472835A1 Fused bicyclic pyrimidine derivatives |
| 07/31/2003 | CA2472682A1 Treating stress response with chemokine receptor ccr5 modulators |
| 07/31/2003 | CA2472367A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | CA2472239A1 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
| 07/31/2003 | CA2472238A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| 07/31/2003 | CA2471989A1 2-aminothiazole allosteric enhancers of a1 adenosine receptors |
| 07/31/2003 | CA2471740A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 07/31/2003 | CA2471342A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 07/31/2003 | CA2454358A1 Multimeric proteins and methods of making and using same |
| 07/31/2003 | CA2441796A1 Solid orally-dispersible pharmaceutical formulation |
| 07/30/2003 | EP1331224A1 Thiazole or oxazole derivatives |
| 07/30/2003 | EP1331001A1 Novel dispersible and soluble galenic paracetamol formulation, method for its preparation and its applications |
| 07/30/2003 | EP1330459A2 Triptolide analogs for the treatment of autoimmune and inflammatory disorders |
| 07/30/2003 | EP1330455A1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same |
| 07/30/2003 | EP1330452A2 Pyrazine derivatives as modulators of tyrosine kinases |
| 07/30/2003 | EP1330448A2 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 07/30/2003 | EP1330444A2 Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof |
| 07/30/2003 | EP1330436A1 N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr3-3 receptor antagonists |
| 07/30/2003 | EP1330432A2 Substituted alkanoic acids |
| 07/30/2003 | EP1330430A2 Integrin receptor inhibitors |
| 07/30/2003 | EP1330425A2 C-nitroso compounds and use thereof |
| 07/30/2003 | EP1330268A1 Targeted therapeutic agents |
| 07/30/2003 | EP1330263A2 Method for down-regulating ige |
| 07/30/2003 | EP1330238A1 Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| 07/30/2003 | EP1330166A1 Food grade transglutaminase inhibitor and uses thereof |
| 07/30/2003 | EP1233960B1 Polymorphic salt of an anti-migraine drug |
| 07/30/2003 | EP1187817B1 Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same |
| 07/30/2003 | EP1184388B1 Sulphostin analogues and processes for the preparation of sulphostin and analogues thereof |
| 07/30/2003 | EP1161234B1 Treatment of pulmonary hypertension by inhalation of benzindene prostaglandins |
| 07/30/2003 | EP1082962B1 Utilization of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factors nf-(k)b |
| 07/30/2003 | EP1075256B1 Arylhydrocarbon receptor ligand antagonists |
| 07/30/2003 | EP0983058B1 Medicinal aerosol products |
| 07/30/2003 | EP0981355B1 Treatment of chronic inflammatory diseases with cm101/gbs toxin |
| 07/30/2003 | EP0946541B1 Quinolines and their therapeutic use |
| 07/30/2003 | EP0942780B1 Coated particles, methods of making and using |
| 07/30/2003 | EP0828736B1 Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
| 07/30/2003 | CN1433477A Method of achieving persistent transgene expression |
| 07/30/2003 | CN1433469A Therapeutically useful synthetic oligonucleotides |
| 07/30/2003 | CN1433424A 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens |
| 07/30/2003 | CN1433416A N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamideinhibitors of cyclin dependent kinases |
| 07/30/2003 | CN1433415A N-[5-[[[5-alkyl-2-oxazlyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases |
| 07/30/2003 | CN1433414A Benzazole derivatives and their use as JNK modulators |
| 07/30/2003 | CN1433412A Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same |
| 07/30/2003 | CN1433411A Chemical compounds |
| 07/30/2003 | CN1433410A CDK inhibitors having 3-hydroxychromen-4-one structure |
| 07/30/2003 | CN1433408A Aminothiazole inhibitors of cyslin dependent kinases |
| 07/30/2003 | CN1433405A Quinazoline compounds |
| 07/30/2003 | CN1433396A Pharmaceutical compounds |
| 07/30/2003 | CN1433318A Vascular endothelial growth factor-2 |
| 07/30/2003 | CN1433316A Biologically active agents and drugs |
| 07/30/2003 | CN1433309A Dual-release compositions of cyclooxygenase-2-inhibitor |
| 07/30/2003 | CN1433300A Treatment agent |
| 07/30/2003 | CN1432410A External prepn for stopping skin pain quickly |
| 07/30/2003 | CN1432392A Wind dispelling and pain relieving ointment |
| 07/30/2003 | CN1432384A Ointment for removing necrosis, promoting granulation and invigorating bone and its prepn |
| 07/30/2003 | CN1432381A Chinese medicine for treating various rheumarthritis |
| 07/30/2003 | CN1432377A Plaster for treating rheumatic diseases and psoatic strain and its prepn process |
| 07/30/2003 | CN1432357A Fever allaying prepn containing xylitol |